Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results